Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers

Brain

Volumn 133, Issue 8, 2010, Pages 2475-2488

  De Felice, Milena ^a   Ossipov, Michael H ^a   Wang, Ruizhong ^a   Dussor, Gregory ^a   Lai, Josephine ^a   Meng, Ian D ^b   Chichorro, Juliana ^c   Andrews, John S ^d   Rakhit, Suman ^d   Maddaford, Shawn ^d   Dodick, David ^e   Porreca, Frank ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NEW ENGLAND   (United States)

^c FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^d NeurAxon Inc   (Canada)

^e MAYO CLINIC   (United States)

Author keywords

Cutaneous allodynia; Medication overuse; Migraine; Nitric oxide; NNOS; Triptans

Indexed keywords

ANALGESIC AGENT; CALCITONIN GENE RELATED PEPTIDE; NEURONAL NITRIC OXIDE SYNTHASE; NXN 323; OXYGENASE INHIBITOR; SUMATRIPTAN; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENZYME INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; TRYPTAMINE DERIVATIVE;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG INDUCED HEADACHE; ENVIRONMENTAL STRESS; ENZYME INHIBITION; MIGRAINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SENSITIZATION; TRIGEMINUS GANGLION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DURA MATER; ENZYMOLOGY; MALE; MENTAL STRESS; METABOLISM; PAIN; PATHOPHYSIOLOGY; PHYSIOLOGY; SENSORY NERVE CELL; SPRAGUE DAWLEY RAT;

ANIMALS; CALCITONIN GENE-RELATED PEPTIDE; DURA MATER; ENZYME INHIBITORS; MALE; MIGRAINE DISORDERS; NEURONS, AFFERENT; NITRIC OXIDE SYNTHASE TYPE I; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; PAIN; RATS; RATS, SPRAGUE-DAWLEY; STRESS, PSYCHOLOGICAL; SUMATRIPTAN; TRIGEMINAL GANGLION; TRYPTAMINES;

EID: 77957024006     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awq159     Document Type: Article

References (101)

1. Afridi SK, Kaube H, Goadsby PJ. Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain 2004; 110: 675-680
2. Akerman S, Williamson DJ, Kaube H, Goadsby PJ. Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br J Pharmacol 2002; 137: 62-68
3. Arulmani U, Maassenvandenbrink A, Villalon CM, Saxena PR. Calcitonin gene-related peptide and its role in migraine pathophysiology. Eur J Pharmacol 2004; 500: 315-330
4. Ayzenberg I, Obermann M, Nyhuis P, Gastpar M, Limmroth V, Diener HC, et al. Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures. Cephalalgia 2006; 26: 1106-1114
5. Bahra A, Walsh M, Menon S, Goadsby PJ. Does chronic daily headache arise de novo in association with regular use of analgesics? Headache 2003; 43: 179-190
6. Barton-Donovan K, Blanchard EB. Psychosocial aspects of chronic daily headache. J Headache Pain 2005; 6: 30-39
7. Bartsch T, Goadsby PJ. The trigeminocervical complex and migraine: current concepts and synthesis. Curr Pain Headache Rep 2003; 7: 371-376
8. Bellamy J, Bowen EJ, Russo AF, Durham PL. Nitric oxide regulation of calcitonin gene-related peptide gene expression in rat trigeminal ganglia neurons. Eur J Neurosci 2006; 23: 2057-2066
9. Bigal ME, Ashina S, Burstein R, Reed ML, Buse D, Serrano D, et al. Prevalence and characteristics of allodynia in headache sufferers: a population study. Neurology 2008; 70: 1525-1533
10. Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology 2008; 71: 1821-1828
11. Bigal ME, Lipton RB. Excessive opioid use and the development of chronic migraine. Pain 2009; 142: 179-182
12. Boer R, Ulrich WR, Klein T, Mirau B, Haas S, Baur I. The inhibitory potency and selectivity of arginine substrate site nitric-oxide synthase inhibitors is solely determined by their affinity toward the different isoenzymes. Mol Pharmacol 2000; 58: 1026-1034
13. Boes CJ, Black DF, Dodick DW. Pathophysiology and management of transformed migraine and medication overuse headache. Semin Neurol 2006; 26: 232-241
14. Bolay H, Moskowitz MA. The neurobiology of migraine and transformation of headache therapy. In: Waxman S, editor. From neuroscience to neurology: neuroscience, molecular medicine, and the therapeutic transformation of neurology. San Diego: Elsevier; 2004. p. 107-123
15. Brain SD, Hughes SR, Cambridge H, O'Driscoll G. The contribution of calcitonin gene-related peptide (CGRP) to neurogenic vasodilator responses. Agents Actions 1993; 38 (Spec No):C19-21.
16. Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain 2001; 89: 107-110
17. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000; 123 (Pt 8): 1703-1709
18. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004; 55: 19-26.
19. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol 2004; 55: 27-36.
20. Burstein R, Levy D, Jakubowski M. Effects of sensitization of trigeminovascular neurons to triptan therapy during migraine. Rev Neurol 2005; 161: 658-660
21. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol 2000; 47: 614-624
22. Centonze V, Bassi A, Causarano V, Dalfino L, Cassiano MA, Centonze A, et al. Sumatriptan overuse in episodic cluster headache: lack of adverse events, rebound syndromes, drug dependence and tachyphylaxis. Funct Neurol 2000; 15: 167-170
23. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL, et al. Quantitative assessment of tactile allodynia in the rat paw. J Neuro Meth 1994; 53: 55-63.
24. Christiansen I, Thomsen LL, Daugaard D, Ulrich V, Olesen J. Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura. Cephalalgia 1999; 19: 660-7; discussion 26.
25. Coderre TJ, Yashpal K. Intracellular messengers contributing to persistent nociception and hyperalgesia induced by L-glutamate and substance P in the rat formalin pain model. Eur J Neurosci 1994; 6: 328-334
26. Cohen AS, Goadsby PJ. Functional neuroimaging of primary headache disorders. Curr Neurol Neurosci Rep 2004; 4: 105-110
27. Dahlof CG, Dodick D, Dowson AJ, Pascual J. How does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials. Headache 2002; 42: 99-113.
28. Dalkara T, Zervas NT, Moskowitz MA. From spreading depression to the trigeminovascular system. Neurol Sci 2006; 27 (Suppl. 2): S86-90.
29. De Felice M, Ossipov MH, Wang R, Lai J, Chichorro JG, Meng I, et al. Triptan-induced latent sensitiation: A possible basis for medication overuse headache. Annals of Neurology 2010; 67: 325-337
30. De Felice M, Porreca F. Opiate-induced persistent pronociceptive trigeminal neural adaptations: potential relevance to opiate-induced medication overuse headache. Cephalalgia 2009; 29: 1277-1284
31. de Hoon JN, Pickkers P, Smits P, Struijker-Boudier HA, Van Bortel LM. Calcitonin gene-related peptide: exploring its vasodilating mechanism of action in humans. Clin Pharmacol Ther 2003; 73: 312-321
32. Diener HC, Dahlof CGH. Headache associated with chronic use of substances. In: Olesen J, Tfelt-Hansen P, Welch K, editors. The Headaches. Philadelphia: Lippincott, Williams & Wilkins; 1999. p. 871-878
33. Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurol 2004; 3: 475-483
34. Dixon WJ. Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 1980; 20: 441-462
35. Dodick D, Freitag F. Evidence-based understanding of medicationoveruse headache: clinical implications. Headache 2006; 46 (Suppl. 4): S202-11.
36. Dowson AJ, Dodick DW, Limmroth V. Medication overuse headache in patients with primary headache disorders: epidemiology, management and pathogenesis. CNS Drugs 2005; 19: 483-497
37. Edvinsson L, Elsas T, Suzuki N, Shimizu T, Lee TJ. Origin and co-localization of nitric oxide synthase, CGRP, PACAP, and VIP in the cerebral circulation of the rat. Microsc Res Tech 2001; 53: 221-228
38. Ekbom K, Krabbe A, Micieli G, Prusinski A, Cole JA, Pilgrim AJ, et al. Cluster headache attacks treated for up to three months with subcutaneous sumatriptan (6 mg). Sumatriptan Cluster Headache Long-term Study Group. Cephalalgia 1995; 15: 230-236
39. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5- HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002; 22: 633-658
40. Freire MA, Guimaraes JS, Leal WG, Pereira A. Pain modulation by nitric oxide in the spinal cord. Front Neurosci 2009; 3: 175--81.
41. Ghiotto N, Sances G, Galli F, Tassorelli C, Guaschino E, Sandrini G, et al. Medication overuse headache and applicability of the ICHD-II diagnostic criteria: 1-year follow-up study (CARE I protocol). Cephalalgia 2009; 29: 233-243
42. Goadsby PJ. Is medication-overuse headache a distinct biological entity? Nat Clin Pract Neurol 2006; 2: 401.
43. Goadsby PJ. The vascular theory of migraine-a great story wrecked by the facts. Brain 2009; 132: 6-7.
44. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28: 183-187
45. Gordh T, Karlsten R, Kristensen J. Intervention with spinal NMDA, adenosine, and NO systems for pain modulation. Ann Med 1995; 27: 229-234
46. Guy N, Marques AR, Orliaguet T, Lanteri-Minet M, Dallel R, Clavelou P. Are there differences between cephalic and extracephalic cutaneous allodynia in migraine patients? Cephalalgia 2009.
47. Hashizume M, Yamada U, Sato A, Hayashi K, Amano Y, Makino M, et al. Stress and psychological factors before a migraine attack: A time-based analysis. Biopsychosoc Med 2008; 2: 14.
48. Hesslinger C, Strub A, Boer R, Ulrich WR, Lehner MD, Braun C. Inhibition of inducible nitric oxide synthase in respiratory diseases. Biochem Soc Trans 2009; 37: 886-891
49. Hou M, Kanje M, Longmore J, Tajti J, Uddman R, Edvinsson L. 5-HT(1B) and 5-HT(1D) receptors in the human trigeminal ganglion: co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthase. Brain Res 2001; 909: 112-120
50. Hughes SR, Brain SD. Nitric oxide-dependent release of vasodilator quantities of calcitonin gene-related peptide from capsaicin-sensitive nerves in rabbit skin. Br J Pharmacol 1994; 111: 425-430
51. Humphrey PP, Goadsby PJ. The mode of action of sumatriptan is vascular? A debate. Cephalalgia 1994; 14: 401-10; discussion 393.
52. Iversen HK, Olesen J, Tfelt-Hansen P. Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain 1989; 38: 17-24.
53. Juhasz G, Zsombok T, Modos EA, Olajos S, Jakab B, Nemeth J, et al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 2003; 106: 461-470
54. Katsarava Z, Jensen R. Medication-overuse headache: where are we now? Curr Opin Neurol 2007; 20: 326-330
55. Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia 2007; 27: 394-402.
56. Khalil Z, Khodr B. A role for free radicals and nitric oxide in delayed recovery in aged rats with chronic constriction nerve injury. Free Radic Biol Med 2001; 31: 430-439
57. Landy S, Rice K, Lobo B. Central sensitisation and cutaneous allodynia in migraine: implications for treatment. CNS Drugs 2004; 18: 337-342
58. Lassen LH, Ashina M, Christiansen I, Ulrich V, Grover R, Donaldson J, et al. Nitric oxide synthase inhibition: a new principle in the treatment of migraine attacks. Cephalalgia 1998; 18: 27-32.
59. Lawson SN, Waddell PJ. Soma neurofilament immunoreactivity is related to cell size and fibre conduction velocity in rat primary sensory neurons. J Physiol 1991; 435: 41-63.
60. Li J, Zhang M, Yang C, Dun Y, Zhang Y, Hao Y. Nitroglycerin protects small intestine from ischemia-reperfusion injury via NO-cGMP pathway and upregulation of alpha-CGRP. J Gastrointest Surg 2009; 13: 478-485
61. Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener HC. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002; 59: 1011-1014
62. Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML, et al. Cutaneous allodynia in the migraine population. Ann Neurol 2008; 63: 148-158
63. Matharu MS, Cohen AS, McGonigle DJ, Ward N, Frackowiak RS, Goadsby PJ. Posterior hypothalamic and brainstem activation in hemicrania continua. Headache 2004; 44: 747-761
64. Mao J, Price DD, Zhu J, Lu J, Mayer DJ. The inhibition of nitric oxideactivated poly(ADP-ribose) synthetase attenuates transsynaptic alteration of spinal cord dorsal horn neurons and neuropathic pain in the rat. Pain 1997; 72: 355-366
65. Meller ST, Gebhart GF. Nitric oxide (NO) and nociceptive processing in the spinal cord. Pain 1993; 52: 127-136
66. Milligan ED, Mehmert KK, Hinde JL, Harvey LO, Martin D, Tracey KJ, et al. Thermal hyperalgesia and mechanical allodynia produced by intrathecal administration of the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein, gp120. Brain Res 2000; 861: 105-116
67. Neeb L, Reuter U. Nitric oxide in migraine. CNS Neurol Disord Drug Targets 2007; 6: 258-264
68. Offenhauser N, Zinck T, Hoffmann J, Schiemann K, Schuh-Hofer S, Rohde W, et al. CGRP release and c-fos expression within trigeminal nucleus caudalis of the rat following glyceryltrinitrate infusion. Cephalalgia 2005; 25: 225-236
69. Okada-Ogawa A, Porreca F, Meng ID. Sustained morphine-induced sensitization and loss of diffuse noxious inhibitory controls in durasensitive medullary dorsal horn neurons. J Neurosci 2009; 29: 15828-15835
70. Olesen J. The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache. Pharmacol Ther 2008; 120: 157-171
71. Olesen J, Iversen HK, Thomsen LL. Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain. Neuroreport 1993; 4: 1027-1030 (Pubitemid 23242637)
72. Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, et al. The International Classification of Headache Disorders, 2nd Edition. Cephalalgia 2004; 24: 1-160.
73. Olesen J, Burstein R, Ashina M, Tfelt-Hansen P. Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol 2009; 8: 679-690
74. Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26: 742-746
75. Paemeleire K, Bahra A, Evers S, Matharu MS, Goadsby PJ. Medicationoveruse headache in patients with cluster headache. Neurology 2006; 67: 109-113
76. Pardutz A, Krizbai I, Multon S, Vecsei L, Schoenen J. Systemic nitroglycerin increases nNOS levels in rat trigeminal nucleus caudalis. Neuroreport 2000; 11: 3071-3075
77. Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 1990; 101: 746-752 (Pubitemid 20357206)
78. Rivat C, Laboureyras E, Laulin JP, Le RC, Richebe P, Simonnet G. Nonnociceptiveenvironmental stress induces hyperalgesia, not analgesia, in pain and opioid-experienced rats. Neuropsychopharmacology 2007; 32: 2217-2228
79. Sarchielli P, Alberti A, Codini M, Floridi A, Gallai V. Nitric oxide metabolites,prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia 2000; 20: 907-918
80. Sarchielli P, Alberti A, Russo S, Codini M, Panico R, Floridi A, et al. Nitric oxide pathway, Ca2+, and serotonin content in platelets from patients suffering from chronic daily headache. Cephalalgia 1999; 19: 810-816
81. Schoonman GG, van der Grond J, Kortmann C, van der Geest RJ, Terwindt GM, Ferrari MD. Migraine headache is not associated with cerebral or meningeal vasodilatation-a 3T magnetic resonance angiography study. Brain 2008; 131: 2192-2200
82. Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 2009; 132: 16-25.
83. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55: 754-762
84. nd Edition (ICHD-II)-revision of criteria for 8.2 Medication-overuse headache. Cephalalgia 2005; 25: 460-465
85. Silverman JD, Kruger L. Lectin and neuropeptide labeling of separate populations of dorsal root ganglion neurons and associated " nociceptor" thin axons in rat testis and cornea whole-mount preparations. Somatosens Res 1988; 5: 259-267
86. Silverman JD, Kruger L. Selective neuronal glycoconjugate expression in sensory and autonomic ganglia: relation of lectin reactivity to peptide and enzyme markers. J Neurocytol 1990; 19: 789-801.
87. Supornsilpchai W, le Grand SM, Srikiatkhachorn A. Involvement of pro-nociceptive 5-HT(2A) receptor in the pathogenesis of medication- overuse headache. Headache 2009; 50: 185-197
88. Tanabe M, Nagatani Y, Saitoh K, Takasu K, Ono H. Pharmacological assessments of nitric oxide synthase isoforms and downstream diversity of NO signaling in the maintenance of thermal and mechanical hypersensitivity after peripheral nerve injury in mice. Neuropharmacology 2009; 56: 702-708
89. Tassorelli C, Joseph SA. Systemic nitroglycerin induces Fos immunoreactivity in brainstem and forebrain structures of the rat. Brain Res 1995a; 682: 167-181
90. Tassorelli C, Joseph SA. NADPH-diaphorase activity and Fos expression in brain nuclei following nitroglycerin administration. Brain Res 1995b; 695: 37-44.
91. Tfelt-Hansen P. Triptans vs other drugs for acute migraine. Are there differences in efficacy? A comment. Headache 2008; 48: 601-605
92. Thomsen LL, Kruuse C, Iversen H, Olesen J. A nitric oxide donor (nitroglycerine) triggers genuine migraine attacks. Eur J Neurol 1994; 1: 73-80.
93. Thomsen LL, Olesen J. A pivotal role of nitric oxide in migraine pain. Ann NY Acad Sci 1997; 835: 363-372 (Pubitemid 28046119)
94. Van der Schueren BJ, Lunnon MW, Laurijssens BE, Guillard F, Palmer J, Van Hecken A, et al. Does the unfavorable pharmacokinetic and pharmacodynamic profile of the iNOS inhibitor GW273629 lead to inefficacy in acute migraine? J Clin Pharmacol 2009; 49: 281-290
95. Vetter G, Geisslinger G, Tegeder I. Release of glutamate, nitric oxide and prostaglandin E2 and metabolic activity in the spinal cord of rats following peripheral nociceptive stimulation. Pain 2001; 92: 213-218
96. Wilkinson SM, Becker WJ, Heine JA. Opiate use to control bowel motility may induce chronic daily headache in patients with migraine. Headache 2001; 41: 303-309
97. White KS, Farrell AD. Anxiety and psychosocial stress as predictors of headache and abdominal pain in urban early adolescents. J Pediatr Psychol 2006; 31: 582-596
98. Wu J, Fang L, Lin Q, Willis WD. Fos expression is induced by increased nitric oxide release in rat spinal cord dorsal horn. Neuroscience 2000; 96: 351-357
99. Wu J, Fang L, Lin Q, Willis WD. Nitric oxide synthase in spinal cord central sensitization following intradermal injection of capsaicin. Pain 2001; 94: 47-58.
100. Yao D, Sessle BJ. Nitroglycerin facilitates calcitonin gene-related peptideinduced behavior. Neuroreport 2008; 19: 1307-1311
101. Zhou L, Zhu DY. Neuronal nitric oxide synthase: structure, subcellular localization, regulation, and clinical implications. Nitric Oxide 2009; 20: 223-230